Brief: Genmab Announces Updated Results From Phase 2 Epcore Nhl-6 Study

Genmab A/S

03/09/2025 14:04

Sept 3 (Reuters) - Genmab A/S GMAB.CO:

ANNOUNCES UPDATED RESULTS FROM PHASE 2 EPCORE® NHL-6 STUDY EVALUATING EPCORITAMAB MONOTHERAPY IN OUTPATIENT SETTING IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)

RESULTS SHOWED THAT 92% OF PATIENTS WITH R/R DLBCL RECEIVED FIRST FULL DOSE OF EPCORITAMAB MONOTHERAPY IN AN OUTPATIENT SETTING

Source text: ID:nGNE7mZsVf

Further company coverage: GMAB.CO

 (Gdansk Newsroom)

 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))